Drugs / HS-20117
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07414953 | Mar 2026 → Apr 2027 expected | lung cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06963502 | May 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06621563 | Dec 2024 → Mar 2026 overdue | colorectal cancer, non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT05940116 | Jul 2023 → Jul 2025 overdue | non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06417008 | May 2024 → Jun 2026 overdue | non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-18 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results ESMO TAT ASIA 2026 | HANSOH PHARMA PRESENTED PHASE I DATA OF HS-20117, AN EGFR/C-MET BISPECIFIC ANTIBODY, IN PATIENTS WITH EGFR EXON 20 INSERTION-MUTATED ADVANCED NSCLC hspharm.com ↗
Among 25 safety-evaluable patients, HS-20117 demonstrated a favorable and manageable safety profile, with most Treatment-Related Adverse Events (TRAEs) being Grade 1-2. |
| 2026-06-18 | Hansoh BioMedical R&D Company | Results ESMO TAT ASIA 2026 | 翰森制药公布HS-20117（EGFR/c-MET双特异性抗体）在EGFR ex20ins晚期NSCLC 人群的I期研究数据 hansoh.cn ↗
HS-20117在携带EGFR 20外显子插入突变（EGFR ex20ins）的晚期非小细胞肺癌患者（NSCLC）中表现出良好的抗肿瘤活性，中位无进展生存期（mPFS）为9. 6个月，中位缓解持续时间（mDoR）为16. 6个月. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-18 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | ESMO TAT ASIA 2026 | HANSOH PHARMA PRESENTED PHASE I DATA OF HS-20117, AN EGFR/C-MET BISPECIFIC ANTIBODY, IN PATIENTS WITH EGFR EXON 20 INSERTION-MUTATED ADVANCED NSCLC hspharm.com ↗ |
| 2026-06-18 | Hansoh BioMedical R&D Company | ESMO TAT ASIA 2026 | 翰森制药公布HS-20117（EGFR/c-MET双特异性抗体）在EGFR ex20ins晚期NSCLC 人群的I期研究数据 hansoh.cn ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06621563 ↗ |
| Modality | Monoclonal antibody | “fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody” NCT06417008 ↗ |
| Route | Intravenous | “receive IV infusion of HS-20117” NCT05940116 ↗ |
| Target | EGFR | “HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody.” NCT05940116 ↗ |
| Target | MET | “HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody.” NCT05940116 ↗ |